NTRK1 and neoplasm: While the proven efficacy of TRK inhibitors such as larotrectinib and entrectinib in fusion-positive tumours demonstrates that TRK signalling is a therapeutically targetable pathway, no clinical studies have yet confirmed similar responses in fusion-negative settings.